Main Article Content
Extraskeletal manifestations (EM) are often observed in ankylosing spondylitis (AS). The available data on the association of EM with inflammatory activity and other clinical parameters of AS are contradictory.
The purpose of the study was to evaluate the association of EM with inflammatory activity and other manifestations of AS.
Patients and methods. At the Tashkent state clinic hospital examined 100 patients (89 men and 11 women) diagnosed with AS according to the New York criteria (1984). The median age of patients was 31.5 years, the age of onset of the disease was 19.5 years and its duration - 11.5 years. 97 (97%) patients identified HLA-B27. In addition to the standard clinical, laboratory and instrumental examination, 52 patients underwent transthoracic echocardiography, ultrasound diagnostics of the kidneys, colonoscopy, consultations of an ophthalmologist, dermatologist, nephrologist, gastroenterologist. Uveitis, heart damage (impaired conduction, changes in the aorta and valves), inflammatory bowel disease (IBD) and psoriasis were considered as EMs. 18 (18%) of 100 patients had uveitis, 21 (21%) had cardiac conduction disorders, 17 (17%) had psoriasis, 6 (6%) had IBD, 41 (41%) out of 100 - changes in the aorta and heart valves. The I group of patients with EM (n=35) and II group without EM (n=65) were compared according to the age of onset of AS, the presence of HLA-B27, arthritis of the peripheral joints, coxitis, enthesitis, syndesmophytes, fever, anemia, and the need for gene- engineering therapy, biological drugs (GIBD) and / or systemic glucocorticoids (GC), the value of the BASDAI, BASMI, BASFI, ASDAS indices, VASc scale and ESR.
Results. The groups with and without EM were comparable in terms of gender, age, duration of AS, and the presence of HLA-B27. There were no significant differences in the ESR, BASDAI, frequency of coxitis, enthesitis, syndesmophytes in the spine.
In the group with EM peripheral arthritis was significantly more common than in the group without EM – in 29 (82.8%) of 35 and in 42 (65,6%) of 65 patients, respectively (p<0.0001) ; fever - in 4 (11,4%) of 35 and 8 (12,3%) of 65 patients, respectively (p<0.0001), anemia- in 9 (25,7%) of 35 and 16 (24,6%) of 65 patients, respectively (p<0.0001); use of GIBP and/or systemic GCs -in 18 (51,4%) of 35 and 26 (40,0%) of 65 patients, respectively (p<0.0001).
Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis. 2007 Aug;66(8):1072-7. Epub 2007 Jan 29. doi: 10.1136/ard.2006.064543.
El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: Prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011 Dec;22(6):554-60. doi: 10.1016/j.ejim.2011. 06.006. Epub 2011 Jul 13.
Zarco P, Gonzalez C, Rodriguez de la Serna A, et al. Extra-articular disease in patients with spondyloarthritis. Baseline characteristics of the spondyloarthritis cohort of the AQUILES study. Reumatol Clin. 2015 Mar-Apr;11(2):83-9. doi: 10.1016/ j.reuma.2014.04.003. Epub 2014 Nov 11.
Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Jan;74(1):65-73. doi: 10.1136/annrheumdis2013-203582. Epub 2013 Sep 2.
Yang P, Wang H, Zhang Z, et al. Clinical diagnosis and treatment of uveitis associated with ankylosing spondylitis. Zhonghua Yan Ke Za Zhi. 2005 Jun;41(6):515-8.
Gouveia E, Elmann D, Morales M. Ankylosing spondylitis and uveitis: overview. Rev Bras Reumatol. 2012 Oct;52(5):742-56. doi: 10.1590/S0482-50042012000500009.
Brunner F, Kunz A, Weber U, Kissling R. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population. Clin Rheumatol. 2006 Feb;25(1):24-9. Epub 2005 Oct 25.
Ljung L, Sundström B, Smeds J, et al. Patterns of comorbidity and disease characteristics among patients with ankylosing spondylitis-a cross-sectional study. Clin Rheumatol. 2017 Nov 8. doi: 10.1007/s10067- 017-3894-0. [Epub ahead of print].
Roldan CA, Chavez J, Wiest PW, et al. Aortic root disease associated with ankylosing spondylitis. J Am Coll Cardiol. 1998 Nov; 32(5):1397-404.
Przepiera-Bezak H, Peregud-Pogorzelska M, Brzosko M. Activity of the disease and selected echocardiographic abnormalities in ankylosing spondylitis. Pol Merkur Lekarski. 2006 Mar; 20(117):296-8.
Essers I, Ramiro S, Stolwijk C, et al. Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):214-21. Epub 2016 Feb 2.
Richette P, Tubach F, BrebanM, et al. soriasis and phenotype of patients with early in ammatory back pain. Ann Rheum Dis. 2013 Apr;72(4):566-71. doi: 10.1136/ annrheumdis-2012-201610. Epub 2012 Jun 7.
Peeters AJ, van den Wall Bake AW, van Dalsen AD, Westedt ML. Relation of microscopic haematuria in ankylosing spondylitis to circulating IgA containing immune complexes. Ann Rheum Dis. 1988 Aug;47(8):645-7.
Van der Linden S, Valkenburg H, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal to modification of the New York criteria. Arthritis Rheum. 1984 Apr;27(4):361-8.
Rakhimova M. B., Akhmedov K. S., Turaev Y. A. Endothelial dysfunction as a link in the pathogenesis of ankylosing spondylitis against the background of a new coronavirus infection //ACADEMICIA: An International Multidisciplinary Research Journal. – 2021. – Т. 11. – №. 3. – С. 2493-2498.